Background: Recent factor-analytic studies in obsessive-compulsive disorder (OCD) identified consistent symptom dimensions. Support for the validity of these dimensions comes from studies of psychiatric comorbidity, functional brain imaging, genetic transmission, and treatment response to medications. This study examined whether previously identified OCD symptom dimensions are associated with treatment compliance and response to behaviour therapy (BT) for OCD. Methods: One hundred and fifty-three OCD outpatients who participated in a multi-centre randomised controlled trial of computer- versus clinician-guided BT for OCD were included in the study. Logistic and multiple regression models tested for significant predictors of compliance with and response to BT and relaxation. Results: The patients studied were phenomenologically comparable (including the presence of ‘pure’ obsessions and mental rituals) to those in previous serotonin reuptake inhibitor (SRI) trials and those in clinical epidemiology studies. High scorers on the ‘hoarding’ dimension were more likely to drop out prematurely from the study and tended to improve less. For those completing treatment, the strongest predictor of outcome was pre-treatment severity. Initial depression scores were unrelated to outcome. After controlling for symptom severity, higher scores on the ‘sexual/religious obsessions’ factor predicted poorer outcome with BT, especially when computer-guided. Conclusions: BT is especially indicated for OCD patients with aggressive/checking, contamination/cleaning and symmetry/ordering symptoms. Previous accounts of unsuccessful BT in patients with hoarding symptoms may be due in part to their propensity to drop out earlier from treatment. Patients with sexual/religious obsessions, but not those with mental rituals, might respond less well to traditional BT techniques. Existing treatments need to be refined and/or new treatments developed to improve these patients’ adherence and response to treatment.

Keywords:
Obsessive-compulsive disorder, Symptom dimensions, Behaviour therapy, Exposure and ritual prevention, Outcome predictors
1.
Baer L: Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. J Clin Psychiatry 1994;55:18–23.
2.
van Oppen P, Hoekstra RJ, Emmelkamp PM: The structure of obsessive-compulsive symptoms. Behav Res Ther 1995;33:15–23.
3.
Hantouche EG, Lancrenon S: Modern typology of symptoms and obsessive-compulsive syndromes: results of a large French study of 615 patients. Encephale 1996;22:9–21.
4.
Leckman JF, Grice DE, Boardman J, Zhang H, Vitale A, Bondi C, Alsobrook J, Peterson BS, Cohen DJ, Rasmussen SA, Goodman WK, McDougle CJ, Pauls DL: Symptoms of obsessive compulsive disorder. Am J Psychiatry 1997;154:911–917.
5.
Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L: Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999;159:1409–1416.
6.
Summerfeldt LJ, Richter MA, Antony MM, Swinson RP: Symptom structure in obsessive-compulsive disorder: a confirmatory factor-analytic study. Behav Res Ther 1999;37:297–311.
7.
Calamari JE, Wiegartz PS, Janeck AS: Obsessive-compulsive disorder subgroups: a symptom-based clustering approach. Behav Res Ther 1999;37:113–125.
8.
Mataix-Cols D, Rauch SL, Baer L, Eisen JL, Shera DM, Goodman WK, Rasmussen SA, Jenike MA: Symptom stability in adult obsessive compulsive disorder: Data from a naturalistic two-year follow-up study. Am J Psychiatry 2002;159:263–268.
9.
Mataix-Cols D, Baer L, Rauch SL, Jenike MA: Relation of factor-analyzed symptom dimensions of obsessive-compulsive disorder to personality disorders. Acta Psychiatr Scand 2000;102:199–202.
10.
Frost RO, Steketee G, Williams LF, Warren R: Mood, personality disorder symptoms and disability in obsessive-compulsive hoarders: a comparison with clinical and nonclinical controls. Behav Res Ther 2000;38:1071–1081.
11.
Alsobrook JP, Leckman JF, Goodman WK, Rasmussen SA, Pauls DL: Segregation analysis of obsessive-compulsive disorder using symptom-based factor scores. Am J Med Genet (Neuropsychiatr Genet) 1999;88:669–675.
12.
Rauch SL, Dougherty DD, Shin LM, Alpert NM, Manzo P, Leahy L, Fischman AJ, Jenike MA, Baer L: Neural correlates of factor-analyzed OCD symptom dimensions: A PET study. CNS Spectrums 1998;3:37–43.
13.
Phillips ML, Marks IM, Senior C, Lythgoe D, O’Dwyer A-M, Meehan O, Williams SCR, Brammer MJ, Bullmore ET, McGuire PK: A differential neural response in obsessive-compulsive patients with washing compared with checking symptoms to disgust. Psychol Med 2000;30:1037–1050.
14.
Black DW, Monahan P, Gable J, Blum N, Clancy G, Baker P: Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry 1998;59:420–425.
15.
Marks IM: Fears, Phobias and Rituals. New York, Oxford University Press, 1987.
16.
Ball SG, Baer L, Otto MW: Symptom subtypes of obsessive-compulsive disorder in behavioural treatment studies: a quantitative review. Behav Res Ther 1996;34(1):47–51.
17.
Christensen H, Hadzai-Pavlovic D, Andrews G, Mattick R: Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1987;55:701–711.
18.
Alonso MP, Menchón JM, Pifarré J, Mataix-Cols D, Torrres L, Salgado P, Vallejo J: Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry 2001;62:535–540.
19.
Greist JH, Marks IM, Baer L, Kobak KA, Wenzel KW, Hirsch MJ, Mantle JM, Clary CM: Behavior therapy for obsessive compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry 2002;63:138–145.
20.
Marks IM, Lelliott P, Basoglu M, Noshirvani H, Montero W, Kasvikis Y: Clomipramine, self-exposure and therapist aided exposure in obsessive-compulsive ritualisers. Brit J Psychiatry 1988;152:522–534.
21.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Part I: Development, use and reliability. Arch Gen Psychiatry 1989;46:1006–1011.
22.
Steketee G, Frost RO, Bogart K: The Yale-Brown Obsessive Compulsive Scale: Interview versus self-report. Behav Res Ther 1996;34:675–684.
23.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
24.
Christensen DD, Greist JH: The challenge of obsessive-compulsive disorder hoarding. Primary Psychiatry 2001;8(2):79–86.
25.
Rasmussen SA, Eisen JL: Clinical and epidemiological findings of significance to neuropharmacologic trials in obsessive-compulsive disorder. Psychopharmacol Bull 1988;24:466–470.
26.
de Araujo LA, Ito LM, Marks IM: Early compliance and other factors predicting outcome of exposure for obsessive-compulsive disorder: results from a controlled study. Brit J Psychiatry 1996;169:747–752.
27.
Frost RO, Gross RC: The hoarding of possessions. Behav Res Ther 1993;31:367–381.
28.
Steketee G, Frost RO, Wincze J, Greene KAI, Douglass H: Group and individual treatment of compulsive hoarding: A pilot study. Behav Cognit Psychother 2000;28:259–268.
29.
Winsberg ME, Cassic KS, Koran LM: Hoarding in OCD: A report of 20 cases. J Clin Psychiatry 1999;60:591–597.
30.
Frost RO, Steketee G: Hoarding: Clinical aspects and treatment strategies; in Jenike MA, Baer L, Minichiello WE (eds): Obsessive Compulsive Disorder: Practical Management, ed 3. St. Louis, Mosby Press, 1998, pp 533–554.
31.
Hartl TL, Frost RO: Cognitive-behavioral treatment of compulsive hoarding: a multiple baseline experimental case study. Behav Res Ther 1999;37:451–461.
32.
Shafran R, Tallis F: Obsessive-compulsive hoarding: a cognitive-behavioural approach. Behav Cognit Psychother 1996;24:209–221.
33.
Foa EB, Kozak MJ, Steketee G, McCarthy PR: Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behavior therapy. Brit J Clin Psychol 1992;31:279–292.
34.
Basoglu M, Lax T, Kasvikis Y, Marks IM: Predictors of improvement in obsessive-compulsive disorder. J Anx Dis 1988;2:299–317.
35.
Goodman WK, Rasmussen SA, Price LH: Type of obsessive-compulsive symptoms and response to clomipramine. Presented at the 1989 annual meeting of the American College of Neuropsychopharmacology.
36.
Salkovskis PM, Westbrook D: Behaviour therapy and obsessional ruminations: Can failure be turned into success? Behav Res Ther 1989;27:149–160.
37.
Freeston MH, Ladouceur R, Rheaume J: Cognitive behavioural treatment of obsessive thoughts. J Consult Clin Psychol 1997;65:405–413.
38.
Abramowitz JS, Brigidi BD, Foa EB: Health concerns in patients with obsessive-compulsive disorder. J Anx Dis 1999;13(5):529–539.
39.
Kozak MJ, Foa EB: Obsessions, overvalued ideas, and delusions in obsessive-compulsive disorder. Behav Res Ther 1994;32:343–353.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.